There is scarce information available in regards to the survival outcome of non-Hodgkin lymphoma (NHL) in South East Asia regions. Reports on the outcome of High dose therapy followed by autologous haematopoietic stem cell transplantation (AHSCT) were mainly from developed countries. In this study, we present the outcome of NHL patients treated with AHSCT from year 1997 to 2016 in two urban hospitals in Malaysia. A total of 140 patients were identified, majority of whom had B cell lymphoma (54.3%). Majority of patients (89.3%) were in complete remission at AHSCT. The overall survival (OS) and event-free survival (EFS) at 3 years were 70.7% and 62.1% respectively. The transplant-related mortality was 3.4%.